Development and Evaluation of Dry Powder Inhalation System of Terbutaline Sulphate for Better Management of Asthma
Keywords:
Turbutaline sulphate, microspheres, pulmonary delivery, Dry powder inhalationAbstract
Terbutaline sulphate (TBS), a bronchodilator (β2 agonist) has a short half-life, hence frequent administration (4-6 times a day) is necessary, resulting in patient compliance problems. Therefore long acting TBS inhalation formulations are desirable to improve patient compliance, reduce toxicity and hence achieve better management of asthma. Microparticulate dry powder inhalation delivery systems for sustained pulmonary drug delivery have been particularly attractive. In the present investigation, TBS loaded chitosan microspheres for pulmonary delivery were prepared by emulsification and ionotropic gelation method. The microspheres were characterized for drug content, particle size, densities, flow properties, moisture content and surface topography by SEM; in vitro drug release was evaluated in simulated lung fluid at 370 at pH 7.4. The respirable or fine particle fraction (FPF) was determined by using twin stage impinger (TSI). Further stability evaluation of TBS loaded DPI systems was carried out at 250/ 60% RH and at 400C/ 75% RH.
References
Courrier H.M.; Butz N.; and Vandamme T.F.
Pulmonary drug delivery systems: Recent
developments and prospects. Crit. Rev.
Therpeut. Drug Carrier Systems 2002, 19, 425-
Groneberg D.A.; Witt C.; Wagner U.; Chung K.
F. and Fischer A. Fundamentals of pulmonary
drug delivery. Respir. Med. 2003, 97, 382-387.
Zeng X. M.; Martin G. P.; and Marriott C. The
controlled delivery of drugs to the lung. Int. J.
Pharm. 1995;124: 149-164.
Witek T. J. The Fate of Inhaled Drugs: The
pharmacokinetics and pharmacodynamics of
drugs administered by aerosol. Respir. Care
, 45, 826-830.
Clark A. R. Pulmonary Delivery Technology:
Recent Advances and Potential for the New
Millennium. In: Anthony J. Hickey editor.
Pharmaceutical Inhalation Aerosol Technology.
nd ed. New York: Marcel Dekker Inc, 2004.
-84.
Byron P. R. Prediction of drug residence times
in regions of the human respiratory tract
following aerosol inhalation. J. Pharm. Sci.
, 75, 433-438.
Shenfield G. M.; Evans M. E. and Paterson J.
W. Absorption of drugs by the lung. Br. J. Clin.
Pharm. 1976, 3,1218-1223.
Adjei A. and Gupta P. Dry-powder inhalation
aerosols. In A. L. Adjei A. L., P. K. Gupta
(eds.), Inhalation Delivery of Therapeutic
Peptides and Proteins. M. Dekker, New York.
, 625–665.
Weers J. Dispersible powders for inhalation
applications. Innov. Pharm. Technol. 2000,
,111-116.
Duddu S.; Sisk S. and Walter Y. Improved lung
delivery from a passive dry powder inhaler
using an engineered PulmoSphere powder.
Pharm. Res. 2002, 19, 689-695.
Smolensky M. H.; D’Alonzo G. E.; Kunkel G.
and Barnes P. J. Day-night patterns in bronchial
patency and dyspnoea: Basis for one daily and
unequally divided twice daily dosing schedules.
Chronobio. Int. 1987, 4,303-307.
Moebus K.; Siepmann J. and Bodmeier R.
Alginate–poloxamer microparticles for
controlled drug delivery to mucosal tissue.
Europ. J. Pharma. And Biopharm.2009, 72 (1),
-53.
Martinac A.; Filipovic-Grcic J.; Voinovich D.;
Perissutti B. and Franceschinis E. Development
and bioadhesive properties of chitosanethylcellulose microspheres for nasal delivery,
Int. J. Pharm. 2005, 291, 69-77.
Mi F.; Wong T.; Shyu S. and Chang S. Chitosan
microspheres: modification of polymeric anti--
physical properties of spray dried microspheres
to control the release of antibiotic drug. J. Appl.
Polm. Sci. 1999, 71, 747–759.
Berthold K.; Cremer J. and Kreuter J.
Preparation and characterization of chitosan
microspheres as drug carrier for prednisolone
sodium phosphate as model for antiinflammatory drugs, J. Control. Release. 1996,
, 17–25.
Lamprecht A.; Helena R.; Ulrich S. and ClausMichael L. Biodegradable microparticles as a
two-drug controlled release formulation: a
potential treatment of inflammatory bowel
disease. J. Control. Release. 2000, 69, 445–454.
Peniche C.; Waldo A.; Hazel P. and Niuris A.
Chitosan: An attractive biocompatible polymer
for microencapsulation, Macromol. Biosci.
, 3, 511–520.
Anal A.; Willem F. and Carmen R. Ionotropic
cross-linked chitosan microspheres for
controlled release of ampicillin, Int. J. Pharm.
, 312, 166–173.
Lim L.; Wan L. and Thai P. Chitosan
microspheres prepared by emulsification and
ionotropic gelation. Drug Dev. Ind. Pharm.
, 23, 981–985.
Nishioka Y.; Kyotani S.; Okamura M.;
Miyazaki M.; Okazaki K.; Ohnishi S.;
Yamamoto Y. and Ito K. Release characteristics
of cisplatin chitosan microspheres and effect of
containing chitin. Chem. Pharm. Bull. 1990, 38,
–2873.
Staniforth J. Improvement in dry powder inhaler
performance: Surface passivation effects. 1996,
Proc. Drug Delivery Lungs (London) VII, 86–
Lucas P.; Anderson K.; Potter U. and Staniforth
J. Enhancement of small particle size dry
powder aerosol formulations using an ultra low
density additive. Pharm. Res. 1999,16, 1643–
Louey M.; Razia S. and Stewart P. Influence of
physicochemical carrier properties on the in
vitro aerosol deposition from interactive
mixtures. Int. J. Pharm. 2003, 252 (1–2), 87–98.
